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Abstract
TBP-1 /Tat-Binding Protein 1 (also named Rpt-5, S6a or PSMC3) is a multifunctional protein, originally identified as a regulator
of HIV-1-Tat mediated transcription. It is an AAA-ATPase component of the 19S regulative subunit of the proteasome and, as
other members of this protein family, fulfils different cellular functions including proteolysis and transcriptional regulation. We
and others reported that over expression of TBP-1 diminishes cell proliferation in different cellular contexts with mechanisms
yet to be defined. Accordingly, we demonstrated that TBP-1 binds to and stabilizes the p14ARF oncosuppressor increasing its
anti-oncogenic functions. However, TBP-1 restrains cell proliferation also in the absence of ARF, raising the question of what
are the molecular pathways involved. Herein we demonstrate that stable knock-down of TBP-1 in human immortalized
fibroblasts increases cell proliferation, migration and resistance to apoptosis induced by serum deprivation. We observe that
TBP-1 silencing causes activation of the Akt/PKB kinase and that in turn TBP-1, itself, is a downstream target of Akt/PKB.
Moreover, MDM2, a known Akt target, plays a major role in this regulation. Altogether, our data suggest the existence of a
negative feedback loop involving Akt/PKB that might act as a sensor to modulate TBP-1 levels in proliferating cells.
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Introduction
TBP1/Tat-Binding Protein 1 (also named Rpt-5, S6a or
PSMC3) is a member of a large highly conserved gene family of
ATPases (ATPAses Associated to a variety of cellular Activities)
whose key feature is a highly conserved module of 230 aa
consisting of an ATPase and a DNA/RNA helicase motif. This
protein family fulfils a large diversity of cellular functions including
cell cycle regulation, gene expression, vesicle mediated transport,
peroxisome assembly and proteasome function [1]. Indeed, as
other members of the family, TBP-1 is associated with the 19S
regulatory subunit of the proteasome, the chief site of protein
destruction in eukaryotic cells [2]. The last 10 years have
highlighted the essential role of proteolysis in governing cell
physiology. Protein breakdown is required not only for removal of
abnormal or aged proteins, but also to control most biological
pathways through the regulated degradation of key cellular factors.
Moreover, abnormal proteasome expression levels have been
described in many tumor cells and proteasome plasma levels
appear elevated in neoplastic patients, underlying the involvement
of the proteasome in cancer development [3,4]. Consistent with
the role in protein destruction, TBP-1 has been shown to bind the
tumour suppressor VHL (Von-Hippel-Landau) gene product [5]
contributing to its E3-ubiquitin ligase function towards the Hif1-a
factor, thus acting as a bona fide tumor suppressor.
On the other hand, 19S protein components (TBP-1 among
them) behave as multifaceted proteins, being implicated in
different cellular events that do not require proteolysis like
transcriptional initiation and elongation, [6,7,8] Nucleotide
Excision Repair [9] and regulation of mitosis [10].
We and others have reported that TBP-1 may function as a
negative regulator of cell proliferation: inhibition of the oncogenic
phenotype of erb-B transformed cells was accompanied by an
increase of TBP-1 intracellular levels and, accordingly, its
overexpression in erb-B transformed cells strongly inhibited tumour
formation in athymic mice [11]; furthermore, TBP-1 overexpres-
sion in different cellular contexts diminished cell proliferation
[11,12]. Our reported results [12,13] showing that TBP-1
enhances the levels of the p14ARF oncosuppressor well fit with
TBP-1 proposed antioncogenic role [11]. On the other hand, the
observation that TBP-1 overexpression can inhibit cell prolifera-
tion also in ARF minus contexts [11,12] suggests an ARF-
independent role of TBP-1, raising the question of what molecular
pathways may be involved.
In this paper, we address the role of TBP-1 in the control of cell
proliferation. To this aim we used, as model, a primary human
fibroblast cell line immortalized by h-TERT (human telomerase)
expression where p14ARF levels are undetectable and in which we
have silenced the expression of TBP-1. Our results show that
cellular levels of TBP-1 are critical in the control of cell
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e22800proliferation pointing to a functional relationship between TBP-1
and the Akt/PKB serine-threonine kinase, one of the major
transducers of growth signals mediating proliferative and pro-
survival effects.
Results
TBP-1 depletion determines an increase in the growth
properties
We decided to first study the effects of long term silencing of
TBP-1 in an immortalized human fibroblast cell line (T11hT). To
this purpose, by retrovirus infection, we generated stable T11hT-
derived cell clones that constitutively express a sh-RNA specifically
designed to silence TBP-1 expression (see Materials and Methods).
As shown in Figure 1A, TBP-1 is efficiently silenced in six stable
clones analyzed, with an extent of silencing ranging from 80% to
48%. To exclude that reduced expression of TBP-1 may have
altered proteasome assembly and function [14], we analyzed
intracellular levels of proteasome subunits other than TBP-1 in
three of the silenced clones (T1, T10E and T10C). In all cases we
observed that the levels of expression of three different proteasome
subunits (Rpt-6, Rpt-1 of the 19S subunit and C8 of the 20S
subunit) do not change significantly as compared to parental
T11hT (Figure 1B). Furthermore, we didn’t observe any variation
of the in vitro proteasome activity of cell extracts obtained from
TBP-1-silenced clones and parental cells on two different peptide
substrates (data not shown).
We then measured the growth rate of the T1 and T10C clones
as compared to that of the T11hT cells. Figure 2A shows that both
the TBP-1 silenced clones analysed proliferate at higher rate
respect to the parental T11hT cell line. In particular, the T1 clone,
expressing very low TBP-1 levels (see Figure 1), grows at a rate
that is roughly twice that of the parental cell line. Moreover, serum
deprivation doesn’t appreciably alter the growth rate of the
silenced clones (Figure 2B). To exclude any clonal secondary effect
due to the selection process, we also generated, by stable
transfection, T11hT cell pools either containing the sh-TBP-1
vector or the empty vector. As it is shown in Figure 2C and D,
TBP-1 silenced cells, although in a less pronounced way respect to
single clones, display the same growth profile, both in presence
and absence of serum.
The enhanced growth rate in TBP-1 silenced cells seems to
be dependent on TBP-1 silencing. In fact, transient expression
of TBP-1 in the faster proliferating T1 clone dramatically
reduces its proliferation rate, both in presence (Figure 2E) and
absence (Figure 2F) of serum; however, after 48 hrs, when the
expression of exogenous TBP-1 was greatly reduced (see
Figure 2E and F, lower panels), cells start to proliferate faster
suggesting that slow proliferating TBP-overexpressing cells
were selected against.
Consistently with the ability of TBP-1 silenced clones to
actively proliferate even in the absence of serum, the cell viability
of the T1 clone, measured after 6 hrs of serum withdrawal,
remains high. In particular, T11hT cell viability was reduced
from 60% to 10% (depending on cell density), while that of the
T1 clone is reduced only up to 60% at the lowest cell density
(Figure 3A and B). We thus investigated whether TBP-1 silencing
may increase cell resistance to serum withdrawal-induced
apoptosis. As shown in Figure 3C and D, the T1 clone behaves
more resistant to serum-deprivation, respect to the parental cells,
as assessed by the very faint amounts of both Caspase-3 and
PARP-1 cleavage. Accordingly, flow cytometry analysis indicates
that serum starvation only slightly affects the percentage of T1
cells in S phase (8% reduction), while more drastically reduces
that of the parental cell line (55% reduction) (Figure 3E).
Furthermore, the increase of the sub-G1 population (of around
1.8 fold for the T1 clone and 3,14 fold for the parental cell line) is
consistent with PARP-1 and Capase-3 cleavage data (Figure 3E
and see 3C and D).
Next, we analyzed the invading capability of the T1 clone
respect to control cells by a chemoinvasion assay in which cells
were plated on Matrigel coated filters and allowed to migrate. As
shown in Figure 4A, as compared to parental cells, T1 cells possess
a moderate but significant higher ability to migrate through
Matrigel. Interestingly, similar results are also obtained when cells
were allowed to migrate toward a generic chemoattractant as EGF
(Epidermal Growth Factor) (Figure 4B). To further prove that the
difference in invasion ability could be ascribed to the reduction of
TBP-1 protein levels and not to any clonal secondary effects,
making use of a specific siRNA, we transiently silenced TBP-1 in
parental T11hT cells. Consistently, transient silencing of TBP1 is
even more effective than stable silencing in T1 cells in inducing a
Figure 1. Characterization of TBP-1 silenced clones. A, B: Cells
stably transfected with TBP1 sh-RNA plasmid or control cells (wt T11hT,
Human Primary Fibroblasts Immortalized by hTERT) were cultured in
DMEM+10%FBS for 24 hrs. Levels of TBP-1 expression was evaluated by
Western Blot with anti-TBP-1 on whole protein lysates. B: As control,
protein levels of other proteasome components (two 19S-ATPases, Rpt-
1 and Rpt-6, and a 20S component, C8) was evaluated in the clones T1,
T10C and T10E. Bands intensity was evaluated by ImageQuant analysis
on at least two different expositions to assure the linearity of each
acquisition, each normalised for the respective actin values. Asterisk,
fold value is expressed relative to the reference point (i.e. TBP-1 levels in
T11hT cells), arbitrarily set to 1. Representative of at least four
independent experiments.
doi:10.1371/journal.pone.0022800.g001
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PLoS ONE | www.plosone.org 2 October 2011 | Volume 6 | Issue 10 | e22800Figure 2. TBP-1 knockdown determines an increase in the growth properties. A, B: Cells from the T1, T10C and control cells (wt T11hT)
were cultured in DMEM either in the presence (A) or in absence (B) of 10% FBS. Cells were collected at the time points indicated and counted in a
Burker chamber. The values are the mean 6 SE of three experiments performed in triplicate. C, D: wt T11hT cells, cells from control cell pool or from
the sh-TBP-1 cell pool were cultured in DMEM either in the presence (C) or in absence (D) of 10% FBS. Cells were collected at the time points
indicated and counted in a Burker chamber. The values are the mean 6 SE of three experiments performed in triplicate. E, F: Cells from the T1 clone
were transfected by electroporation with empty vector (indicated just as T1) or TBP-1 expression plasmid (indicated as T1+TBP-1); cells were then
cultured either in the presence (E) or in absence (F) of 10%FBS and collected at the time points indicated (being T0 the time at 24 hours after
transfection). Cells from each time point have been counted in a Burker chamber. Values are mean 6 SE of two experiments performed in triplicate
and are indicated as values relative to the reference point (T0). E, F lower panels: TBP-1 expression and Akt activation have been evaluated by
Western Blot with anti-TBP-1, anti-Phospho-Akt Ser473, anti-Akt and anti-actin, as loading control, on whole protein lysates of cells collected at each
time point, as indicated.
doi:10.1371/journal.pone.0022800.g002
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PLoS ONE | www.plosone.org 3 October 2011 | Volume 6 | Issue 10 | e22800Figure 3. TBP-1 knockdown reduces sensitivity to serum starvation. A, B: Cells from the T1 clone and control cells (wt T11hT) were plated at
different cell densities as indicated, either in the presence or absence of 10% FBS. After six hrs from plating, cell viability was measured by MTS assay.
In the histograms, cell viability is expressed as relative to controls, arbitrarily set to 100 (%). The values are the mean 6 SE of three experiments
performed in quintuplicate. C, D: 1.8610
5 cells/35 mm plates from the T1 clone and control cells (wt T11hT) were grown for 24 hrs, in the presence
or absence of 10% FBS. Apoptosis was checked by detection of Caspase-3 (C) and PARP-1 (D) cleavage in Western Blot. Detection with anti-actin was
included for control of equal loading. Bands Intensity was measured by ImageQuant analysis on at least two different expositions to assure the
linearity of each acquisition. Representative of at least four independent experiments. E: T11hT and T1 cells were counted and seeded at 2610
5cells/
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Matrigel invasion was likely due to an increased invading
capability of TBP1 silenced cells, as also suggested by the fact
that we don’t observe any difference both in the expression and
activation status of the EGF receptor (not shown).
Taken together these data show that TBP-1 sensitizes cells to
apoptosis induced by serum withdrawal and interferes with cell
growth and migration.
TBP-1 inhibits Akt/PKB activation
The observation that TBP-1 depletion allows cells to grow in a
serum-independent manner, prompted us to ask whether TBP-1
expression levels may control, in some way, the activity of the Akt/
PKB serine-threonine kinase, one of the major transducers of
growth signals, critical for cell proliferation and apoptosis. We thus
evaluated the levels of phospho-Akt in our TBP-1 depleted clones,
under actively growth conditions (i.e. in the presence of serum). As
35 mm plate. At 24 hrs cells were collected and treated for analysis of cellular DNA content by flow cytometry. Percentages of cells in the SubG1, G0–
G1, S and G2–M phases were quantified with Summit 4.1 software. Representative of three different experiments. The numerical ratios reported on
the right highlight the different behaviour of T1 cells when grown in absence or presence of serum. Table 1 provides the mean values (and standard
deviations in parentheses) relative to this analysis.
doi:10.1371/journal.pone.0022800.g003
Figure 4. Silencing of TBP-1 determines an increase of the invading capability. A: Cells from the T1 clone or control cells (wt T11hT) were
plated in Boyden chambers and allowed to migrate on filters coated with Matrigel. The values are the mean 6 SE of three experiments performed in
triplicate. (*) p=0.046 as determined by the Student’s t test. B: Cells from the T1 clone or control cells (wt T11hT) were plated in Boyden chambers
and allowed to migrate toward EGF on Matrigel filters. 100% values represent cell migration in the absence of chemoattractants. The values are the
mean 6 SE of three experiments performed in triplicate. (*) p=0.027 as determined by the Student’s t test. C: Cells transiently transfected with TBP1
si-RNA or with the control si-RNA (si-Luc) were plated in Boyden chambers and allowed to migrate toward EGF on filters coated with Matrigel. 100%
values represent cell migration in the absence of chemoattractants. The values are the mean6SE of three experiments performed in triplicate. (*)
p=0.016 as determined by the Student’s t test.
doi:10.1371/journal.pone.0022800.g004
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the extent of silencing of TBP-1, being the lowest in the parental
T11hT and the highest in the T1 clone. Consistently, we observed
an increase in the extent of phosphorylation of GSK3b, a well
characterized Akt/PKB direct target. TBP-1 reduction appears to
specifically affect Akt activation but not that of other important
transducers of growth signals, like ERK1/2. Furthermore, in
agreement with the observed higher proliferation rate of the
clones, we observed a reduction of phospho-cyclin D1 protein
levels (data not shown). Both in parental cells and in TBP-1
silenced clones, Akt activation appears to be dependent on the
upstream phosphatidylinositol 3-kinase activity (PI3K) as evi-
denced by Wortmannin and LY294002 treatment that block PI3K
activity (Figure 5B).
Importantly, we could reproduce, in T11hT cells, the same
effect after transient reduction of TBP-1 levels by siRNA: silencing
of TBP-1 was accompanied by a concomitant increase in the
steady-state level of pAkt, suggesting the existence of a causal
relationship between TBP-1 intracellular levels and Akt activation
(Figure 5C). This effect was not cell-specific since we could
reproduce it in the U2OS osteosarcoma-derived cells (Figure 5D).
Further, we set up a rescue experiment in which we re-
established high TBP-1 levels in the T1 clone by transient
overexpression. In these conditions we observed a strong reduction
of pAkt levels (Figure 5E and see also Figure 2E, F). Consistently,
insulin-mediated activation of Akt in a different cellular context
(U2OS cells) is counteracted by TBP-1 overexpression (Figure 5F).
Altogether these data suggest that TBP-1 levels modulate the
extent of Akt/PKB activation.
TBP-1 is a downstream target of Akt activation
The new insights into the role of TBP-1 in the control of cell
growth prompted us to investigate whether TBP-1 protein levels
are sensitive to acute growth factors stimulation. We thus
stimulated either T11hT or U2OS osteosarcoma cells by insulin
treatment for the indicated time periods and analyzed protein
lysates by Western Blots with anti-TBP-1 antibodies. Figure 6A
clearly shows that insulin treatment results in a rapid, transient
drop of TBP-1 intracellular levels; indeed, TBP-1 levels are
reduced of around two times in 5 min and remain low up to
40 minutes with a kinetic that mirrors that of the activation of
Akt/PKB (Figure 6A, left panel). On the other hand, other
proteasome subunits (Rpt-6 and C8) protein levels remain almost
stable or, at least, slightly increased, following insulin treatment
(Figure 6A). To test the effects of inhibition of the PI3K/Akt
pathway on TBP-1 protein levels, U2OS cells or T11hT cells were
treated for the indicated time periods with PI3K inhibitors and
protein lysates analyzed by Western Blots. As shown in Figure 6B,
inhibition of the PI3K/Akt pathway determines a slight though
reproducible increase in TBP-1 endogenous levels, suggesting that
they are either directly or indirectly regulated by PI3K activity.
Again, in these conditions, other proteasome subunits (Rpt-6 and
C8) protein levels remain stable (Figure 6B, left panel). To further
confirm these observations, we transiently transfected increasing
amounts of a constitutively active mutant of the Akt kinase (CA-
Akt) in U2OS cells. Overexpression of CA-Akt was accom-
panied by a reduction of endogenous TBP-1 levels, while other
proteasome subunits protein levels remain unchanged (Figure 6C).
Taken together, these data strongly indicate that TBP-1 protein
levels are modulated by the Akt/PKB activity.
On the other hand, by immunoprecipitation experiments we
were unable to observe any physical interaction between TBP-1
and Akt/PKB (data not shown), suggesting that TBP-1 levels are
indirectly modulated by Akt activation. We thus wondered which
could be the mediator of Akt/PKB action on TBP-1.
Among the known Akt/PKB effector is the MDM2 protein that,
following phosphorylation by Akt/PKB, increases its activity
[15,16,17]. We thus determined whether MDM2 mediates the
functional relationship between TBP-1 and Akt/PKB. In order to
obtain Akt activation, we treated with insulin U2OS cells that were
previously either treated with a MDM2 specific siRNA or, as
control, with a luciferase siRNA (Figure 6D). Interestingly, MDM2
silencing prevented the reduction of TBP-1 intracellular levels
following treatment with insulin, although has no effects on TBP-1
basal levels. Consistently, the increase in TBP-1 levels following
treatment with PI3K inhibitors, is prevented in cells in which
MDM2 is silenced (Figure 6E), suggesting that, indeed, silencing of
MDM2 renders Akt activation/inactivation ineffective on TBP-1
levels. These data strongly implicate MDM2 to be needed, even
not sufficient, for TBP-1 regulation by Akt/PKB. Involvement of
MDM2 is supported by co-immunoprecipitation experiments in
U2OS cells. As shown in Figure 7A and 7B we found TBP-1 in
complex both with endogenous and with transfected MDM2.
Furthermore, we observed that overexpression of MDM2 causes a
decrease of TBP-1 intracellular levels (Figure 7A and B, see input).
We confirmed this observation transfecting U2OS cells with fixed
concentration of pcDNA-TBP-1 and increasing amounts of the
MDM2 expression plasmid (Figure 7C). Since the observed effect
occurs both on the endogenous and on the exogenous protein, it is
likely that MDM2 acts on TBP-1 at the post-transcriptional level.
Moreover, treatment of U2OS cells with the proteasome inhibitor
MG132 counteracts the MDM2 effect on TBP-1, indicating the
proteasome as the final effector of the MDM2 action on TBP-1
(Figure 7D).
We thus asked if mutations in MDM2 that render it less
responsive to Akt/PKB stimulation [15,16,17,18] reduces, as well,
its ability to downregulate TBP-1 levels. The MDM2S166A and
MDM2S166A/186A mutants appear almost unable to mediate TBP-
1 degradation (Figure 7E), indicating that only a functionally Akt-
responsive MDM2 molecule, could regulate TBP-1 levels.
Accordingly, a MDM2 deletion mutant that lacks all the Akt
target sites in MDM2 (MDM2D150–230) [19] appear unable to act
on TBP-1 levels (Figure 7F). Interestingly, a MDM2 mutant,
lacking the ring finger domain (MDM21–441), is still able to act on
TBP-1 (Figure 7F), indicating that MDM2 is not acting on TBP-1
levels through its ubiquitination activity.
Table 1. Mean values (and standard deviations in parentheses) relative to the flow cytometry analysis described in Figure 3.
T11hT
+serum
T11hT
2serum
T1
+serum
T1
2serum
Sub-G1 12,69 (+/22,35) 39,79 (+/25,02) 13,02 (+/21,8) 29,05 (+/23,12)
S 14,87 (+/21,2) 6,44 (+/20,9) 13,94 (+/21,75) 14,13 (+/22,49)
doi:10.1371/journal.pone.0022800.t001
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PLoS ONE | www.plosone.org 6 October 2011 | Volume 6 | Issue 10 | e22800Figure 5. TBP-1 knockdown determines activation of the Akt/PKB kinase. A: Cells from the T1, T10C and control cells (wt T11hT) were
cultured in DMEM+10%FBS for 24 hrs. Activation of Akt/PKB was revealed by Western Blot with anti-Phospho-Akt Ser473 antibody. As control,
extracts were also probed with anti-Akt, anti-Phospho-GSK-3b/pSer219, anti-pERK1/2, anti-ERK1/2 and anti-actin antibodies. Bands Intensity was
measured by ImageQuant analysis on at least two different expositions to assure the linearity of each acquisition, each normalised for the respective
actin values. Asterisk, fold value is expressed relative to the reference point, arbitrarily set to 1. Representative of at least four independent
experiments. B: Cells from the T1 clone or control cells (wt T11hT) were plated at the cell density of 2.5610
5 in DMEM+10%FBS in six wells. After
24 hrs, either DMSO (/) or with Wortmannin or LY294002, where indicated, were added to the cells at the concentrations indicated and left for either
1 hour (with Wortmannin) or 159(with LY294002). Extracts were then probed in Western Blot with antibodies against Akt, Phospho-Akt Ser473 and
actin. C, D: T11hT cells (C) or U2OS cells (D) were transfected with an siRNA directed against TBP-1 or Luciferase. Extracts were probed with
antibodies against Phospho-Akt Ser473, Akt and actin. E: Cells from the T1 clone were transfected with empty vector (first lane) or increasing
amounts of TBP-1 expression plasmid. Activation of Akt/PKB was evaluated by Western Blot on whole protein lysates probed with anti-Phospho-Akt
TBP-1 and Akt in the Control of Cell Proliferation
PLoS ONE | www.plosone.org 7 October 2011 | Volume 6 | Issue 10 | e22800These data provide clear evidence that TBP-1 is a downstream
target of the Akt/PKB-MDM2 axis, even though the molecular
mechanisms through which MDM2 acts on TBP-1 remain to be
elucidated.
Discussion
Herein we report data showing that reduction of TBP-1
intracellular levels affects cell proliferation, invading capabilities
and resistance to apoptosis of human fibroblasts immortalized by
h-TERT expression. Interestingly, unlike the parental cells,
proliferation of TBP-1 silenced clones appears to be serum-
independent. Our data indicate that TBP-1 modulates the extent
of activation of the Akt/PKB kinase, a critical effector of
intracellular signaling. In fact, we demonstrate that reduction of
TBP-1 intracellular levels causes the activation of the Akt signaling
pathway. It has to be underlined that this can be directly ascribed
to TBP-1 depletion rather than to clonal secondary effects as it also
occurs after transient silencing of TBP-1 and irrespective of the cell
type. Remarkably, transient expression of TBP-1 in one of the
silenced clones restores phospho-Akt basal levels and drastically
reduces the proliferation rate. Furthermore, TBP-1 overexpression
in other cellular systems prevents Akt/PKB activation thus
confirming that TBP-1 can act upstream of Akt.
Activation of the Akt/PKB pathway plays a central role in
tumorigenesis. Indeed, Akt is overexpressed in many different
tumour cell types, with a burgeoning list of substrates implicated in
oncogenesis [20]. In principle, the increase of Akt/PKB activity
could account for all the changes induced by TBP-1 silencing (i.e.
proliferation, cell viability, escape from apoptosis, migration
capabilities) [21,22,23,24]. On the other hand, the acquisition of
a transformed phenotype is a quite complex stepwise accumulation
of genetic changes [25,26]. In this context, it seems plausible to
predict that, by acting on Akt/PKB, down-modulation of TBP-1
intracellular levels might contribute to the acquisition of a
transformed phenotype thus cooperating with other genetic
lesions. Since TBP-1 silenced clones are normal fibroblasts that
only bear h-TERT overexpression to guarantee immortalization,
an intriguing possibility to explore is the introduction of ‘‘key’’
cellular lesions to cause cell transformation in these clones.
The mechanism by which TBP-1 prevents Akt/PKB activation
remains an open question. Even though, like the other AAA-
ATPases of the 19S base of the proteasome, TBP-1 is supposed to
act by conferring specificity to the proteasome [27,28] various
observations suggest that TBP-1 may act, as well, in a proteasome
independent manner [6,7,8,12,13,29]. Indeed, the proteasome
seems very unlikely involved in the modulation of the Akt/PKB
activity by TBP-1. In fact, an increase in the proliferation rate is
frequently associated to an increase of proteasome levels needed to
guarantee high metabolic activity. Here we show that TBP-1
silenced clones don’t display a significant alteration in proteasome
composition and activity. Furthermore, unlike other proteasome
components (C8 and Rpt-6), TBP-1 responds to acute insulin
stimulation with a decrease of its intracellular levels. In a different
context, other proteasome subunits respond to growth factor
stimulation with an increase of intracellular levels [30].
It has to be underlined that we have already observed that TBP-
1 stabilizes p14ARF [12,13] avoiding ARF entrance into the
proteasome. We retain that TBP-1 could play a role in ARF
folding, rendering it a poor substrate for degradation by the 20S as
well as by the 20S/11S proteasome [31,32]. The existence of a
similar mechanism that permits to TBP-1 to increase the
intracellular levels of proteins that regulate Akt/PKB activity is
the subject of further studies.
Furthermore, our results reveal the existence of a reciprocal
regulatory loop where Akt/PKB activation leads to TBP-1
reduction and, in turn, TBP-1 overexpression prevents Akt/PKB
activation. In this scenario, the Akt/PKB kinase thus might act as
a sensor that modulates TBP-1 levels in actively duplicating cells.
On the other hand, based on the fact that the PI3K/Akt signaling
effect on TBP-1 is prevented in cells in which MDM2 is silenced,
we propose, as mediator of the PI3K/Akt signaling on TBP-1, the
MDM2 protein, one of the main direct targets of Akt/PKB
activation [15,16,17,18]. Actually, MDM2 can bind to TBP-1 and
its overexpression causes a reduction of TBP-1 intracellular levels.
Strikingly, the MDM2S166A/S186A mutant and the MDM2D150–230,
lacking Akt responsive sites, are unable to act on TBP-1 protein
levels, likely placing TBP-1 downstream of the Akt/PKB-MDM2
axis.
Even though the specific mechanism for MDM2-dependent
depression of TBP-1 levels remains to be understood, it has to be
noted that MDM2 has multifaceted roles in protein degradation.
In fact, aside its well-described role as E3-ubiquitin ligase, under
appropriate stimuli, MDM2 can shuttle p63 to the cytoplasm
mediating its interaction with proteins specifically involved in its
turnover [33]. Moreover, MDM2 has been shown to mediate
proteasome-dependent but ubiquitin-independent degradation of
p21
Waf1/Cip1 [19] and of Retinoblastoma Protein [34] through
direct binding with the C8 subunit of the 20S proteasome. On the
other hand, it has very recently been reported that MDM2
interacts with components of the 19S proteasome in a ubiquityla-
tion independent manner [35] claiming a wider view of its
mechanism of action.
Interestingly, the MDM2D150–230 mutant was described to be
unable to shuttle between the nucleus and the cytoplasm,
displaying a predominant cytoplasmic localization [19]. This
could imply that the MDM2 action on TBP-1 levels requires its
nuclear localization that, indeed is described to occur following
phosphorylation by Akt [15,18].
Moreover, the fact that the MDM21–441 deletion mutant, that
lacks the ring finger domain, is still able to act on TBP-1
(Figure 7F), indicates that MDM2 is not acting on TBP-1 levels
through its ubiquitination activity, supporting the possibility that it
rather acts as a molecular cargo and should plausibly act in
concert with other pAkt effector molecule(s) needed to direct TBP-
1 for degradation.
Altogether our observations provide further insights on the
proposed antiproliferative role of TBP-1 [11,12,13], indicating the
involvement of the Akt/PKB kinase. Indeed, we could speculate
that, under standard growing conditions, TBP-1 contributes to
balance Akt/PKB up-regulation; whilst, under growth factor acute
stimulation, activation of the Akt/PKB signaling pathway lowers
TBP-1 levels and initiate a feedback loop. Further, it’s interesting
to underline that the human oncosuppressor p14ARF that is
stabilized by TBP-1 overexpression [12,13] is itself able to
antagonize the activity of Akt/PKB [36] with yet unknown
Ser473 and, as control, with anti-Akt and anti-actin. F: U2OS cells were transfected with empty vector (lanes 1–4) or TBP-1 expression plasmid (lanes 5,
6). After 24 hrs cells were starved for 4 hrs and treated with 10 ng/ml insulin for 109 where indicated. Activation of Akt/PKB was evaluated by Western
Blot on whole protein lysates probed with anti-Phospho-Akt Ser473. Extracts were also probed with anti-Akt, anti-actin and anti-Xpress (to reveal
transfected TBP-1).
doi:10.1371/journal.pone.0022800.g005
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PLoS ONE | www.plosone.org 8 October 2011 | Volume 6 | Issue 10 | e22800Figure 6. TBP-1 is a downstream target of Akt activation. A: U2OS cells or T11hT cells were starved for 4 hrs and then treated with 10 ng/ml
insulin for the times indicated. Activation of Akt/PKB was evaluated by Western Blot on whole protein lysates probed with anti-Phospho-Akt Ser473
and anti-Akt. Levels of endogenous TBP-1 and of two proteasome components (C8 and Rpt-6) were analyzed where indicated. TBP-1 bands intensity
was measured by ImageQuant analysis on two different expositions to assure the linearity of each acquisition, each normalised for the respective
actin values. Asterisk, fold value is expressed relative to the reference point, (i.e. TBP-1 levels in starved cells) arbitrarily set to 1. Representative of
three independent experiments. B: U2OS cells or T11hT cells were treated, 24 hrs after plating, either with DMSO (/) or with 200 nM Wortmannin or
50 mM LY294002 for the times indicated. Cells were then lysed and Western Blot analysis was performed by using specific antibodies against
Phospho-Akt Ser473, anti-Akt, anti-TBP-1, anti-C8 and anti-Rpt-6. TBP-1 bands intensity was calculated as in A. Representative of three independent
experiments. C: U2OS cells were transfected with empty vector (lane 1) or increasing amounts of the constitutive active mutant of the Akt kinase (CA-
Akt). After 24 hrs cells were lysed and whole cell lysates probed with anti-Phospho-Akt Ser473, anti-Akt, anti-TBP-1, anti-Rpt-1, anti-Rpt-6, and anti-
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vivo requirement of ARF for full activation of PTEN, one of the
major negative regulators of Akt activity.
In conclusion, our data well support a role for TBP-1 in the
attenuation of Akt/PKB activity and place this protein with a key
role in the control of cell proliferation. Even though, further
studies are necessary to understand the potential cross-talks linking
TBP-1 action on p14ARF and on Akt/PKB regulation.
Materials and Methods
Cell cultures, viral infection, transfections
T11hT (human primary fibroblasts immortalized by constitutive
expression of the telomerase catalytic subunit h-TERT) human
cell line was kindly provided by dr. Eric Gilson. T1, T10C and
T10E (TBP-1 silenced clones) derived by retroviral infection of
T11hT: briefly, 3610
6 HEK 293-LinX packaging cells (kindly
provided by Prof. Nicola Zambrano) were transfected with
ARREST-IN (Open Biosystems, Huntsville, AL, USA) with
pSUPERIOR.shTBP-1. 24 hrs after transfection, virus containing
supernatant was filtrated through 0,45 mm cellulose acetate
syringe filter, supplemented with 5 mg/ml polybrene, and used
to infect recipient T11hT cells, previously plated at 50%
confluence. Twenty-four hours following infection, 1 mg/ml
G418 was applied to select stably infected cells. After three weeks,
23 individual single G418 resistant clones were picked up and
expanded. Six neomycin resistant colonies from 5 different plates,
were screened by Western Blot with anti-TBP-1.
BothT11hTandTBP-1silencedclonesweregrowninDulbecco’s
Modified Eagle Medium (DMEM) supplemented with 10% Fetal
Bovine serum and 1 mg/ml puromycin (to maintain selection for h-
TERT). U2OS cells were grown in Dulbecco’s Modified Eagle
Medium supplemented with 10% Fetal Bovine serum.
To obtain sh-TBP-1 pool and control pool, 2610
6 T11hT cells
were transfected by electroporation by making use of a Microporator
MP-100 (Digital Bio Technology) either with 3 mgo fp S U P E R -
IOR.shTBP-1 or 3 mg of pSUPERIOR.retro.neo; twenty-four hours
following transfection, 1 mg/ml G418 was applied to select cells. After
four weeks, resistant cells were collected, expanded and analyzed.
Transfection by Lipofectamine2000 were performed as de-
scribed [12].
Transfection of the T1 clone was performed by the use of a
Microporator MP-100 (Digital Bio Technology) using either
2610
6 cells with 2 mg of either pcDNA empty vector or
pcDNATBP-1 (rescue of cell proliferation, Figure 2E and F) or
1610
6 cells with either pcDNA empty vector or pcDNATBP-1
(0.3 or 0.6 mg) (rescue of Akt activation, Figure 5 E). Cells were
then plated in DMEM+10% FBS for 24 hrs at 37uC or DMEM
without FBS at 37uC and collected for subsequent analysis.
For transient silencing experiments, the duplex siRNA oligomer
designed to target human TBP-1 is described in [12]; the duplex
siRNA oligomer targeting human MDM2 has the following
sequence: 59- AAGCCAUUGCUUUUGAAGUUA-39 and was
designed as described in [19]. siRNA were all synthesized by
MWG Biotech, Germany. Either U2OS, T11hT or T1 cells were
transfected by Hyperfect (Quiagen, GmBH, Germany) according
to the manufacturer’s instructions.
Cell growth analysis, MTS assay, Flow cytometry analysis,
Chemoinvasion assay
For cell growth analysis, T11hT parental cell line, T1, T10C
and T10E clones, or T11hT, control pool and sh-TBP-1 pool,
were plated in 100 mm dishes in presence of 10% FBS at the cell
density of 1610
5 cells/plate. Cells were cultured for 24, 48 and
72 hrs, collected, and counted in a Burker chamber. For growth in
the absence of serum, after 6 hrs from plating, medium was
removed and replaced with medium without serum. As above,
cells have been grown for 24, 48 and 72 hrs, collected and
counted. Each point is the result of triplicate samples.
Cell viability was evaluated using the MTS [3-(4,5-di-
methylthiazhol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophe-
nyl)-2H-tetrazolium,inner salt] (Cell Titer 96AQueous assay G358
purchased from Promega) colorimetric assay. Briefly, T11hT
parental cell line or cells derived from the T1 clone were plated at
different cell densities as indicated in 96 well plates (2.5610
3/well,
10
3/well, 3610
2 /well) either in DMEM or in DMEM+10%FBS.
After six hrs from plating, 1:5 MTS solution was added to each
well and the cells were incubated for 309 at 37uC. Plates were read
on a Microplate Reader (BIO-TEK Instruments, Model Elx800)
at 492 nm. Survival was expressed as the percentage of viable cells
in treated samples relative to non-treated control cells. All the
experiments were repeated in quintuplicate.
For flow cytometry analysis, T11hT and T1 cells were counted
and seeded at 2610
5cells/35 mm plate. At 24 hours after plating
the medium was replaced and the cells treated with DMEM
containing 10% Fetal bovin serum or DMEM without serum. At
the indicated time points, cells were collected, centrifuged, washed
twice with PBS 16 and then fixed with ice-cold 70% ethanol.
Fixed cells were incubated with staining buffer solution (50 mg/ml
PI and 50 mg/ml RNase A in PBS pH 7.4) for 20 minute at room
temperature in a dark box. Stained cells were analysed in a
fluorescence-activated cytometer (DakoCytomation). Data on
DNA cell-content were acquired on 20,000 events at a rate of
150650 events/second and the percentages of cells in the SubG1,
G0–G1, S and G2–M phases were quantified with Summit v4.1
software.
Chemoinvasion assays were performed in Boyden chambers
using 8 mm pore size PVPF polycarbonate filters coated with
50 mg/ml of Matrigel. 16105 cells were plated in the upper
chamber in serum-free medium. 100 ng/ml EGF or serum free
medium was added in the lower chamber. Cells were allowed to
migrate for 4 h at 37uC, 5% CO2. To examine basal migration,
serum free medium was added to both upper and lower chamber,
and migration was allowed for 12 h at 37uC, 5% CO2, in the
absence of chemoattractants.
The cells on the lower surface of the filter were then fixed in
ethanol, stained with hematoxylin, and counted at 2006
magnification (10 random fields/filter).
Western Blotting, Immunoprecipitations, Insulin
treatments, MG132 treatment
Western Blots were performed as described [12]. Antibodies to
Akt (used in 1:1000 dilution), Phospho-Akt Ser473 (used in 1:1000
dilution), Phospho-GSK-3b/pSer21/9 (used in 1:1000 dilution),
phospho-GSK3b. D: U2OS cells were transfected with a siRNA directed against MDM2 or Luciferase, as control, at the final concentration of 10 nM.
After 24 hrs, cells were starved for 4 hrs and then treated with 10 ng/ml insulin for the times indicated. Cells were then lysed and Western Blot
analysis was performed by using specific antibodies against Phospho-Akt Ser473, TBP-1, MDM2, Akt, and actin. E: U2OS cells were transfected with a
siRNA directed against MDM2 or Luciferase, as control. After 48 hrs, either DMSO (/) or 200 nM Wortmannin was added to the cells and left for the
times indicated. Cells were then lysed and Western Blot analysis was performed by using specific antibodies against Phospho-Akt Ser473, TBP-1,
MDM2, Akt and actin.
doi:10.1371/journal.pone.0022800.g006
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PLoS ONE | www.plosone.org 10 October 2011 | Volume 6 | Issue 10 | e22800Figure 7. TBP-1 is a downstream target of MDM2 activation. A: U2OS cells were either transfected (lanes +) or untransfected (lanes 2) with
the MDM2 expression plasmid. 24 hrs after transfection cell extract was prepared and subjected either to immunoprecipitation with anti-TBP-1
antibody where indicated or, with anti-GFP antibody as negative control. Cell extracts were also incubated with protein A-agarose as control, where
indicated. Immunoprecipitated extracts were analyzed by Western Blot with anti-MDM2 or anti-TBP-1 antibody. Aliquots of cell extracts were
analyzed by Western Blot before immunoprecipitation (input). B: U2OS cells were either transfected (lanes +) or untransfected (lanes 2) with the
MDM2 expression plasmid. 24 hrs after transfection cell extract was prepared and subjected either to immunoprecipitation with anti-MDM2 antibody
where indicated or, with anti-Flag antibody as negative control. Cell extracts were also incubated with protein A-agarose as control, where indicated.
Immunoprecipitated extracts were analyzed by Western Blot with anti-MDM2 or anti-TBP-1 antibody. Aliquots of cell extracts were analyzed by
Western Blot before immunoprecpitation (input). C: U2OS cells were transfected with TBP-1 expression plasmid and increasing amounts of MDM2
expression plasmid. After 24 hrs, cells were lysed and whole cell extracts probed with anti-TBP-1, anti-MDM2, and anti-actin, for loading control. D:
U2OS cells were transfected with TBP-1 expression plasmid and increasing amounts of MDM2 expression plasmid. After 24 hrs cells were treated
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Cell Signalling Technologies, Boston, MA, USA. Antibodies to
MDM2 (used in 1:500 dilution) was purchased from Calbiochem,
to Rpt-1 (PSMC2) (used in 1:6000 dilution), Rpt6 (PSMC5) (used
in 1:6000 dilution) and C8 (used in 1:6000 dilution) were
purchased from BioMol. Anti-Xpress antibody (used in 1:1000
dilution) was purchased from Invitrogen. Secondary antibodies for
Western Blot analysis (goat anti-rabbit IgG-HRP 1:3000 dilution)
were purchased from Santa Cruz Biotechnology, CA, USA.
Proteins were visualized with an enhanced chemiluminescence
detection system (Amersham ECL
TM) and images were taken with
ChemiDoc XRS System (Bio-Rad Laboratories) and analysed
with the QuantityONE software.
For insulin treatment, U2OS cells were transfected by
Lipofectamine with 0.2 and 0.5 mg of the pcDNATBP-1 plasmid.
At 24 hrs after transfection, cells were starved for 4 hrs and then
treated with 10 ng/ml insulin for 109.
To analyze TBP-1 levels following insulin treatments, either
U2OS cells or T11hT cells were starved for 4 hrs and then treated
with 10 ng/ml insulin for the times indicated.
For immunoprecipitation in U2OS cells, 1.0610
6 cells were
seeded in 100 mm dishes and transfected with the plasmids
indicated in the figure legend. Cells were harvested 24 hours after
transfection and cell lysates were prepared as described [12]:
800 mg of whole cell extract were incubated overnight at 4uC
with anti-TBP1 (BioMol) or anti-MDM2 C18 (Santa Cruz).
Controls of immunoprecipitations were perceived with mouse
anti-GFP (Roche) or rabbit anti-Flag (Sigma). Immunocomplexes
were collected by incubation with 30 ml of protein A-agarose
(Roche Applied Science) at 4uC for 4 hrs. The beads were washed
with Co-Ip buffer (50 mM tris-HCL pH 7.5; 150 mM NaCl;
5 mM EDTA; 0,5% Np40), resuspended in 26 loading buffer
(Sigma) and loaded on a SDS-8% polyacrylamide gel.
Treatment with proteasome inhibitor was performed as follows:
U2OS cells were treated either with DMSO or 10 mM MG132 for
five hours. Cells were harvested and total extracts prepared for
subsequent analysis as described.
Constructs
pSUPERIORshTBP-1 has been obtained from pSUPERIOR.-
retro.neo (Oligoengine) by cloning into BglII-HindII sites a duplex
oligonucleotide obtained by MWG-Biotech that could give rise to
a short hairpin RNA specifically designed to silence TBP-1
expression.
Oligoseq:
59GATCCCCAACAAGACCCTGCCGTACCTT-
CAAGAGAGGTACGGCAGGGTCTTGTTTTTTTA
39
pCA-Akt plasmid was kindly provided by Prof. G. Condorelli.
The MDM21–441 and MDM2D150–230 expression plasmids were
previously described [19].
Plasmids MDM2S166A and MDM2S166A/S186A mutant were
generated by Quick Change Site Direct Mutagenesis Kit
(Stratagene, La Jolla, CA, USA) and amplified using the following
primers:
S166A (F)
59GGAGAGCAATTGCTGAGACAGAAG
39,
S166A (R)
59CTTCTGTCTCAGCAATTGCTCTCC
39
S166A/S186A (F)
59 CGCCACAAAGCTGATAGTATTTCC-
C
39
S166A/S186A (R)
59GGGAAATACTATCAGCTTTGTGG-
CG
39
PCR was performed with a 2720 Thermo Cycler Applied
Biosystem.
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